Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Revenue (2020 - 2025)

Historic Revenue for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $8.2 million.

  • Foghorn Therapeutics' Revenue rose 441.85% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.5 million, marking a year-over-year decrease of 390.75%. This contributed to the annual value of $22.6 million for FY2024, which is 3382.52% down from last year.
  • As of Q3 2025, Foghorn Therapeutics' Revenue stood at $8.2 million, which was up 441.85% from $7.6 million recorded in Q2 2025.
  • Foghorn Therapeutics' Revenue's 5-year high stood at $17.5 million during Q3 2023, with a 5-year trough of $41000.0 in Q3 2021.
  • Moreover, its 5-year median value for Revenue was $5.3 million (2023), whereas its average is $5.2 million.
  • Its Revenue has fluctuated over the past 5 years, first plummeted by 7709.5% in 2021, then soared by 1608048.78% in 2022.
  • Quarter analysis of 5 years shows Foghorn Therapeutics' Revenue stood at $713000.0 in 2021, then skyrocketed by 486.82% to $4.2 million in 2022, then skyrocketed by 37.88% to $5.8 million in 2023, then plummeted by 50.49% to $2.9 million in 2024, then skyrocketed by 185.47% to $8.2 million in 2025.
  • Its Revenue stands at $8.2 million for Q3 2025, versus $7.6 million for Q2 2025 and $6.0 million for Q1 2025.